Patient  ||| S:0 E:8 ||| NN
and  ||| S:8 E:12 ||| CC
treatment  ||| S:12 E:22 ||| NN
perspectives ||| S:22 E:34 ||| NNS
:  ||| S:34 E:36 ||| :
Revisiting  ||| S:36 E:47 ||| NNP
the  ||| S:47 E:51 ||| DT
link  ||| S:51 E:56 ||| NN
between  ||| S:56 E:64 ||| IN
type  ||| S:64 E:69 ||| NN
2  ||| S:69 E:71 ||| CD
diabetes ||| S:71 E:79 ||| NN
,  ||| S:79 E:81 ||| ,
weight  ||| S:81 E:88 ||| NN
gain ||| S:88 E:92 ||| NN
,  ||| S:92 E:94 ||| ,
and  ||| S:94 E:98 ||| CC
cardiovascular  ||| S:98 E:113 ||| JJ
risk  ||| S:113 E:118 ||| NN
Lifestyle  ||| S:118 E:128 ||| NNP
modifications  ||| S:128 E:142 ||| NNS
in  ||| S:142 E:145 ||| IN
conjunction  ||| S:145 E:157 ||| NN
with  ||| S:157 E:162 ||| IN
antidiabetes  ||| S:162 E:175 ||| JJ
medications  ||| S:175 E:187 ||| NN
can  ||| S:187 E:191 ||| MD
produce  ||| S:191 E:199 ||| VB
near-normal  ||| S:199 E:211 ||| JJ
blood  ||| S:211 E:217 ||| NN
glucose  ||| S:217 E:225 ||| NN
concentrations  ||| S:225 E:240 ||| NNS
in  ||| S:240 E:243 ||| IN
patients  ||| S:243 E:252 ||| NNS
with  ||| S:252 E:257 ||| IN
type  ||| S:257 E:262 ||| NN
2  ||| S:262 E:264 ||| CD
diabetes  ||| S:264 E:273 ||| NN
mellitus  ||| S:273 E:282 ||| NNS
( ||| S:282 E:283 ||| -LRB-
T2DM ||| S:283 E:287 ||| NNP
) ||| S:287 E:288 ||| -RRB-
.  ||| S:288 E:290 ||| .
Because  ||| S:290 E:298 ||| IN
these  ||| S:298 E:304 ||| DT
patients  ||| S:304 E:313 ||| NNS
have  ||| S:313 E:318 ||| VBP
increased  ||| S:318 E:328 ||| VBN
cardiovascular  ||| S:328 E:343 ||| JJ
morbidity  ||| S:343 E:353 ||| NN
and  ||| S:353 E:357 ||| CC
mortality ||| S:357 E:366 ||| NN
,  ||| S:366 E:368 ||| ,
treatment  ||| S:368 E:378 ||| NN
strategies  ||| S:378 E:389 ||| NNS
should  ||| S:389 E:396 ||| MD
also  ||| S:396 E:401 ||| RB
address  ||| S:401 E:409 ||| VB
the  ||| S:409 E:413 ||| DT
cardiovascular  ||| S:413 E:428 ||| JJ
aspects  ||| S:428 E:436 ||| NNS
of  ||| S:436 E:439 ||| IN
the  ||| S:439 E:443 ||| DT
disease ||| S:443 E:450 ||| NN
,  ||| S:450 E:452 ||| ,
including  ||| S:452 E:462 ||| VBG
blood  ||| S:462 E:468 ||| NN
pressure ||| S:468 E:476 ||| NN
,  ||| S:476 E:478 ||| ,
lipids ||| S:478 E:484 ||| NN
,  ||| S:484 E:486 ||| ,
and  ||| S:486 E:490 ||| CC
body  ||| S:490 E:495 ||| NN
weight ||| S:495 E:501 ||| NN
.  ||| S:501 E:503 ||| .
Since  ||| S:503 E:509 ||| IN
the  ||| S:509 E:513 ||| DT
prevalence  ||| S:513 E:524 ||| NN
of  ||| S:524 E:527 ||| IN
these  ||| S:527 E:533 ||| DT
abnormalities  ||| S:533 E:547 ||| NN
is  ||| S:547 E:550 ||| VBZ
increasingly  ||| S:550 E:563 ||| RB
secondary  ||| S:563 E:573 ||| JJ
to  ||| S:573 E:576 ||| TO
poor  ||| S:576 E:581 ||| JJ
diet  ||| S:581 E:586 ||| NN
and  ||| S:586 E:590 ||| CC
sedentary  ||| S:590 E:600 ||| JJ
lifestyles  ||| S:600 E:611 ||| NN
and  ||| S:611 E:615 ||| CC
because  ||| S:615 E:623 ||| IN
most  ||| S:623 E:628 ||| JJS
patients  ||| S:628 E:637 ||| NNS
with  ||| S:637 E:642 ||| IN
T2DM  ||| S:642 E:647 ||| NNP
are  ||| S:647 E:651 ||| VBP
overweight ||| S:651 E:661 ||| JJ
/ ||| S:661 E:662 ||| CD
obese ||| S:662 E:667 ||| NN
,  ||| S:667 E:669 ||| ,
clinicians  ||| S:669 E:680 ||| NNS
are  ||| S:680 E:684 ||| VBP
encouraged  ||| S:684 E:695 ||| VBN
to  ||| S:695 E:698 ||| TO
help  ||| S:698 E:703 ||| VB
patients  ||| S:703 E:712 ||| NNS
reduce  ||| S:712 E:719 ||| VB
body  ||| S:719 E:724 ||| NN
weight  ||| S:724 E:731 ||| NN
while  ||| S:731 E:737 ||| IN
correcting  ||| S:737 E:748 ||| JJ
hyperglycemia  ||| S:748 E:762 ||| NN
by  ||| S:762 E:765 ||| IN
selecting  ||| S:765 E:775 ||| VBG
treatment  ||| S:775 E:785 ||| NN
options  ||| S:785 E:793 ||| NNS
that  ||| S:793 E:798 ||| WDT
improve  ||| S:798 E:806 ||| VBP
both  ||| S:806 E:811 ||| DT
parameters ||| S:811 E:821 ||| NN
.  ||| S:821 E:823 ||| .
The  ||| S:823 E:827 ||| DT
glucose-lowering  ||| S:827 E:844 ||| JJ
properties  ||| S:844 E:855 ||| NNS
of  ||| S:855 E:858 ||| IN
insulin  ||| S:858 E:866 ||| NN
and  ||| S:866 E:870 ||| CC
sulfonylureas  ||| S:870 E:884 ||| NNS
are  ||| S:884 E:888 ||| VBP
well  ||| S:888 E:893 ||| RB
known  ||| S:893 E:899 ||| VBN
but  ||| S:899 E:903 ||| CC
they  ||| S:903 E:908 ||| PRP
are  ||| S:908 E:912 ||| VBP
also  ||| S:912 E:917 ||| RB
associated  ||| S:917 E:928 ||| VBN
with  ||| S:928 E:933 ||| IN
weight  ||| S:933 E:940 ||| NN
gain ||| S:940 E:944 ||| NN
.  ||| S:944 E:946 ||| .
Thiazolidinediones  ||| S:946 E:965 ||| NNS
are  ||| S:965 E:969 ||| VBP
associated  ||| S:969 E:980 ||| VBN
with  ||| S:980 E:985 ||| IN
weight  ||| S:985 E:992 ||| NN
gain  ||| S:992 E:997 ||| NN
as  ||| S:997 E:1000 ||| IN
well  ||| S:1000 E:1005 ||| RB
as  ||| S:1005 E:1008 ||| IN
edema ||| S:1008 E:1013 ||| NN
.  ||| S:1013 E:1015 ||| .
However ||| S:1015 E:1022 ||| RB
,  ||| S:1022 E:1024 ||| ,
this  ||| S:1024 E:1029 ||| DT
weight  ||| S:1029 E:1036 ||| NN
gain  ||| S:1036 E:1041 ||| NN
may  ||| S:1041 E:1045 ||| MD
be  ||| S:1045 E:1048 ||| VB
more  ||| S:1048 E:1053 ||| RBR
peripheral  ||| S:1053 E:1064 ||| JJ
than  ||| S:1064 E:1069 ||| IN
central ||| S:1069 E:1076 ||| JJ
,  ||| S:1076 E:1078 ||| ,
which  ||| S:1078 E:1084 ||| WDT
may  ||| S:1084 E:1088 ||| MD
mitigate  ||| S:1088 E:1097 ||| VB
the  ||| S:1097 E:1101 ||| DT
risks  ||| S:1101 E:1107 ||| NNS
associated  ||| S:1107 E:1118 ||| VBN
with  ||| S:1118 E:1123 ||| IN
increased  ||| S:1123 E:1133 ||| JJ
body  ||| S:1133 E:1138 ||| NN
fat ||| S:1138 E:1141 ||| NN
.  ||| S:1141 E:1143 ||| .
Metformin ||| S:1143 E:1152 ||| NNP
,  ||| S:1152 E:1154 ||| ,
the  ||| S:1154 E:1158 ||| DT
consensus  ||| S:1158 E:1168 ||| NN
first-line  ||| S:1168 E:1179 ||| JJ
drug  ||| S:1179 E:1184 ||| NN
for  ||| S:1184 E:1188 ||| IN
the  ||| S:1188 E:1192 ||| DT
treatment  ||| S:1192 E:1202 ||| NN
of  ||| S:1202 E:1205 ||| IN
patients  ||| S:1205 E:1214 ||| NNS
with  ||| S:1214 E:1219 ||| IN
T2DM ||| S:1219 E:1223 ||| NNP
,  ||| S:1223 E:1225 ||| ,
is  ||| S:1225 E:1228 ||| VBZ
weight  ||| S:1228 E:1235 ||| NN
neutral ||| S:1235 E:1242 ||| NN
.  ||| S:1242 E:1244 ||| .
Newer  ||| S:1244 E:1250 ||| JJR
antidiabetes  ||| S:1250 E:1263 ||| JJ
agents  ||| S:1263 E:1270 ||| NNS
include  ||| S:1270 E:1278 ||| VBP
incretin-based  ||| S:1278 E:1293 ||| JJ
medications ||| S:1293 E:1304 ||| NN
,  ||| S:1304 E:1306 ||| ,
such  ||| S:1306 E:1311 ||| JJ
as  ||| S:1311 E:1314 ||| IN
the  ||| S:1314 E:1318 ||| DT
glucagon-like  ||| S:1318 E:1332 ||| JJ
peptide-1  ||| S:1332 E:1342 ||| CD
receptor  ||| S:1342 E:1351 ||| NN
agonists ||| S:1351 E:1359 ||| NN
,  ||| S:1359 E:1361 ||| ,
which  ||| S:1361 E:1367 ||| WDT
tend  ||| S:1367 E:1372 ||| VBP
to  ||| S:1372 E:1375 ||| TO
decrease  ||| S:1375 E:1384 ||| VB
weight ||| S:1384 E:1390 ||| NN
,  ||| S:1390 E:1392 ||| ,
and  ||| S:1392 E:1396 ||| CC
the  ||| S:1396 E:1400 ||| DT
dipeptidyl  ||| S:1400 E:1411 ||| JJ
peptidase-4  ||| S:1411 E:1423 ||| CD
inhibitors ||| S:1423 E:1433 ||| NN
,  ||| S:1433 E:1435 ||| ,
which  ||| S:1435 E:1441 ||| WDT
are  ||| S:1441 E:1445 ||| VBP
weight  ||| S:1445 E:1452 ||| NN
neutral ||| S:1452 E:1459 ||| NN
.  ||| S:1459 E:1461 ||| .
